

October 8, 2025

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Announcement of New Antibody and Reagent Product Launch**

Perseus Proteomics, Inc. ("the Company") is pleased to announce that, as of October 8, 2025, we have launched sales of the "Anti-S1PR3 antibody," suitable for use in disease and metabolic research.

S1PR3 (\*1) is known to be involved in cellular proliferation, angiogenesis, and immune response, and is attracting attention at research institutes worldwide as a therapeutic target for inflammatory diseases and cancer. The newly released antibody features recognition based on the three-dimensional structure of S1PR3, and can be broadly utilized as a research reagent for expression detection, functional analysis assays (\*2), and more.

The Company currently provides a variety of antibodies and reagents to domestic and overseas academic and industrial fields, and we plan to further expand our lineup with new research-use antibody reagents and research support services. Through these initiatives, we aim to respond to the needs of the research community and to expand our revenue base and drive our company's growth.

We will continue striving to enhance our corporate value for shareholders and investors on a continuous basis.

\*1 S1PR3 (Sphingosine-1-phosphate receptor 3) is a G protein-coupled receptor (GPCR) that binds extracellular lipid mediator sphingosine-1-phosphate (S1P).

\*2 Functional analysis assay: An analytical method for evaluating and measuring whether specific functions of biomolecules or cells are operating normally.

End